<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26757">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915615</url>
  </required_header>
  <id_info>
    <org_study_id>U01HL117006-01A1</org_study_id>
    <secondary_id>U01HL117006-01A1</secondary_id>
    <nct_id>NCT01915615</nct_id>
  </id_info>
  <brief_title>HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy</brief_title>
  <acronym>HCMR</acronym>
  <official_title>HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <authority>United States: Data and Safety and Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease  and the most
      frequent cause of sudden cardiac death (SCD) in the young. It is characterized by
      unexplained left ventricular hypertrophy (LVH), diffuse and patchy fibrosis, and
      myofibrillar disarray. While the majority of patients remain asymptomatic, prognosis is poor
      in a subset who present with SCD or progress to heart failure (HF). Current methods to
      predict risk of these adverse events and to target therapy are limited. Current medical
      therapy does not protect against SCD, nor does it prevent development of HF. Therefore, the
      identification of novel risk markers would help develop therapeutic targets aimed at
      altering the phenotypic expression to impact the natural history, especially SCD and HF.
      Cardiovascular magnetic resonance (CMR) is emerging as a powerful tool for diagnosis and
      risk stratification in HCM including assessment of LV mass and pattern of hypertrophy. Late
      gadolinium enhancement by CMR is a marker of focal myocardial fibrosis which is thought to
      underlie the arrhythmogenic substrate as well as promote development of HF. The
      investigators hypothesize that HCM patients with a higher primary outcome event rate can be
      identified by novel CMR findings. The majority of cases of HCM are autosomal dominant and
      about 60% are caused by mutations in genes encoding cardiac sarcomeric proteins. However,
      the relationship between genetic mutation, disease phenotype, and clinical outcomes remains
      poorly understood. The investigators hypothesize that HCM patients with sarcomeric HCM
      mutations will have a higher primary outcome event rate and more marked myocardial pathology
      on CMR than those without. Furthermore, there may be a link between sarcomeric mutations and
      fibrosis, as mutation carriers with overt HCM as well as those without hypertrophy have
      elevated markers of collagen turnover. The investigators therefore hypothesize that serum
      biomarkers of collagen metabolism in HCM will predict outcomes. Thus, the Specific Aim is to
      develop a predictive model of cardiovascular outcomes in HCM by: 1) using exploratory data
      mining methods to identify demographic, clinical, and novel CMR, genetic and biomarker
      variables associated with the outcomes and 2) develop a score from the predictive model that
      can be used to assess risk given a patient's combination of risk factors, thus establishing
      the evidence base to enable clinical trial design to reduce morbidity and mortality in HCM
      in a cost-effective manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2.2 Rationale Presently used risk predictors in HCM for the clinical outcomes of SCD and HF
      are still insufficient and limit clinical trials and institution of novel therapies in this
      disease. This large scale, prospective clinical registry will systematically answer the
      important question whether, through addition of a combination of advanced CMR phenotyping,
      genetic and biomarker analysis, risk stratification in HCM could be substantially improved
      over presently used clinical risk predictors. Emerging novel blood, genetic, and CMR markers
      offer the paradigm-shifting promise of reliably identifying those at risk. In addition, this
      will be the largest genotyped population of HCM available to correlate with comprehensive
      CMR and biomarker evaluation. This will allow unique opportunities to evaluate
      genotype-phenotype correlations and compare specific genetic subsets in a manner that has
      not been possible in the past. This study will also establish a predictive model that can be
      used to assess risk given a patient's combination of risk factors. This will help to select
      patients for future clinical trials to prevent SCD and HF. In addition, it will identify
      surrogate endpoints to monitor treatment response in HCM. In this way, the evidence base
      will be established in HCM to enable clinical trial design to reduce morbidity and mortality
      in HCM in a cost-effective manner.

      3 OBJECTIVES The Specific Aim of this study is to develop a predictive model of
      cardiovascular outcomes in hypertrophic cardiomyopathy by: 1) using exploratory data mining
      methods to identify demographic, clinical, and novel CMR, genetic and biomarker variables
      associated with the outcomes and 2) develop a score from the predictive model that can be
      used to assess risk given a patient's combination of risk factors, thus establishing the
      evidence base to enable clinical trial design to reduce morbidity and mortality in HCM in a
      cost-effective manner.

      To understand the relationship between these novel risk markers in HCM and clinical outcome,
      the investigators propose a natural history study of 2750 patients with clinically diagnosed
      HCM studied at baseline with collection of demographic data, clinical risk factors, as well
      as novel markers from CMR, genotyping, and serum biomarkers of collagen turnover and
      myocardial injury, enrolled over a 2-year period and followed for 3-5 years (mean of 4
      years). The study will be powered to identify risk markers in a Cox model (imaging, serum,
      and genetic beyond standard clinical risk factors) with a hazard ratio of 1.5 or greater for
      the primary endpoint, which will be cardiac death (including SCD and HF death), aborted SCD
      (appropriate discharge of an implantable cardioverter-defibrillator), and need for heart
      transplantation. Secondary endpoints include all-cause mortality, ventricular
      tachyarrhythmias, hospitalization for heart failure, atrial fibrillation, and stroke. This
      study will enable establishment of a predictive model that will help to identify patients at
      risk as well as patients for future clinical trials to prevent SCD and HF. In addition, it
      will identify surrogate endpoints to monitor treatment response in HCM.

      4 STUDY DESIGN 4.1 Selection of the Study Population

      Patient characteristics:

      2750 patients will be recruited and will include at least 51% females and 30% minorities.

      Recruiting locations:

      Inpatient or outpatient setting from 35-40 sites in North America and Europe

      Serum Biomarker and DNA Samples Blood will be collected by peripheral venipuncture at
      enrollment as a source of serum and plasma for biomarker analysis, as well as a source of
      DNA for genetic testing. Fasting samples are requested but if this is not possible
      logistically, non-fasting samples can be acquired and noted as such.  The investigators will
      also ask subjects to refrain from strenuous exercise for 24 hours prior to blood draw to
      decrease the potential for spuriously elevated biomarkers that reflect the influence of
      vigorous physical activity.

      Cardiac MRI

      A cardiac MRI will be performed and will take approximately one hour. 0.15mM of gadolinium
      contrast will be infused through an intravenous line during the MRI.

      Full details of the protocol will be in the Study Manual. Laboratory Evaluations 5.1.1
      Specimen Collection, Preparation, Handling and Shipping Biomarker samples (Full details are
      provided in the separate Biomarkers Technical Manual) 1. Collect 3, 10 ml tubes each of
      serum and K3 EDTA plasma in the fasting state (or indicated non-fasting if fasting samples
      cannot be obtained) DNA samples

      1.  Collect one 10ml EDTA tube. 6 STUDY SCHEDULE 6.1 Screening Patient's medical records
      will be reviewed to be certain of diagnosis and eligibility.

      Informed consent must be obtained by a member of the study team. 6.2 Baseline visit

      Initial visit will be scheduled for study procedures as listed in #5 above. 6.3 Follow-up
      Visits Yearly telephone follow-up will be obtained for up to 5 years and review of
      applicable hospital or death records.  Health status will be assessed with the SF-12 at this
      time.

      10 STATISTICAL CONSIDERATIONS 10.1 Study Outcome Measures

      The primary endpoint of this prospective study is the composite of cardiac death (SCD and HF
      death), aborted SCD including appropriate ICD firing, and need for heart transplantation.

      Secondary endpoints include all-cause mortality, ventricular tachyarrhythmias,
      hospitalization for heart failure, atrial fibrillation, and stroke.

      10.2 Sample Size Considerations Assuming a 3-year event rate of 4.2% based on recently
      published literature10;11;26;27 and alpha error rate of 5%, 2500 patients provides over 90%
      power to detect a hazard ratio of 1.5 for at least one risk factor in the Cox model. An
      additional 250 (2750 total) patients will be enrolled to compensate for a projected dropout
      rate of 2% per year.

      10.3 Participant Enrollment and Follow-Up 2750 enrollees, will be followed up to 5 years.
      10.4 Analysis Plan Because the anticipated event rate is small (4-5%), and the number of
      potential predictive risk factors is large (20+), an exploratory, tree classification
      analysis will be used to identify the strongest predictors and eliminate any that are judged
      to have little or no predictive power. Based on the risk factors identified in the
      exploratory analysis, a regression prediction model will be developed from which a summary
      risk score for HCM can be calculated and easily used in clinical settings.

      Tree-based data mining methods will be used to identify key variables in the prediction of
      the primary outcome, a composite of cardiac death (SCD and HF death), aborted SCD including
      appropriate ICD firing, and need for heart transplantation. Secondary endpoints will include
      all-cause mortality, ventricular tachyarrhythmias, septal myectomy or alcohol ablation,
      hospitalization for heart failure, atrial fibrillation, and stroke. Tree-based modeling is
      an exploratory technique for uncovering structure in multivariate data28;29. It is
      particularly useful for deriving prediction rules from a large number of screening variables
      or risk factors. Tree models can be used for both classification (binary outcome) and
      regression (continuous outcome). In either case, the collection of prediction rules (from
      the predictor variables) is displayed in the form of a tree. The terminology mimics that of
      trees: the root is the top node of the tree that displays the mean (regression) or
      proportion (classification) of the outcome for the entire sample. A split is the rule for
      creating new branches, and a leaf is a terminal node. Each node is a binary split of the
      predictor variable that contains two sub-groups of the sample with the largest possible
      difference between the groups. The same variable can appear in more than one level of the
      tree (recursive partitioning).

      The advantage of tree-based models over linear and additive models is that they are more
      adept at capturing non-additive relationships and more easily uncover complex interactions
      between predictor variables. Continuous variables or categorical variables with more than
      two levels need not be dichotomized prior to the analysis - the tree algorithm determines
      the cutoff value that produces the most homogenous nodes. Missing data can be treated as a
      separate category. Initial tree models will include risk factors listed in the following
      table as well as demographic variables, age, sex, and race.

      Clinical CMR Genetic Biomarkers Family history of HCM-related SCD LV ejection fraction MYH7
      NT-pro BNP Unexplained recent syncope LV mass/mass index MYBPC3 Singulex cardiac troponin
      Massive LVH (wall thickness &gt;30mm) Maximum diastolic wall thickness Thin filament mutations
      PICP Multiiple burst of nonsustained VT LGE extent (% of LV mass) Compound/double
      heterozygotes ST2 Hypotensive BP response to exercise Global extracellular volume fraction
      Sarcomere mutation negative The initial tree is reduced in size (pruned) by comparing
      misclassification error rates of smaller trees to larger trees to assess the reduction of
      the predictive ability of trees resulting from the pruning process.  The goal is to identify
      the strongest predictors of HCM, any interactions of the predictors, and eliminate any
      factors that have little predictive power. While tree models give rapid identification of
      the strongest predictors and combinations of predictors, they do not usually result in
      clinically useful prediction models that generalize well to patients in other settings.
      Regression methods, using test-validation re-sampling procedures, will be used to develop
      the most valid model possible.

      Using the demographic, clinical, imaging, biomarker and genetic measures, plus any
      interactions, identified in the tree analysis, Cox proportional hazards regression will be
      used to develop a predictive model from which a summary risk score can be calculated and
      applied in clinical settings. Parametric regression methods may be used if the proportional
      hazards assumption is not met. The regression model will be developed using a 100-fold
      validation procedure whereby 50% of the observations will be randomly selected for model
      development (test sample) and the remaining 50% used to assess the model's predictive
      ability (validation sample).  This procedure will be repeated 100 times with a different
      random selection of test-validation samples for each iteration. The c-index will be
      calculated to assess model discrimination for both test and validation samples30. The
      ensemble of test-validation models provides an estimate of the attenuation of the c-index
      when the model is applied to a different sample as well as consistency of specific risk
      factors appearing in the models. A final model will be constructed that includes the
      combination of the strongest (high c-index and frequency of appearance) predictors. This
      model will then be applied to the entire sample to estimate regression coefficients and
      hazard ratios and calculate a summary risk score30. Nomograms will be constructed from the
      final model to provide predicted probabilities of the risk scores. To increase the ease of
      use of a nomogram, variables which are statistically significant but have little effect on
      prediction may be excluded. The model will also be used to develop a prediction algorithm
      that rapidly calculates risk on a hand-held electronic device. This analysis may also inform
      the design of clinical trials to evaluate therapeutic efficacy by providing effect sizes
      (hazard ratios) to calculate sample size requirements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sudden cardiac death and heart failure death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aborted sudden cardiac death</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Includes appropriate ICD firing (sustained ventricular tachycardia, rate&gt;200bpm, or ventricular fibrillation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart transplantation</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular assist device placement</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular tachyarrhythmias</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ventricular fibrillation or sustained ventricular tachycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2750</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Hypertrophic cardiomyopathy</arm_group_label>
    <description>None - this is an observational study.
Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after  index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None - this is an observational study</intervention_name>
    <description>None - this is an observational study</description>
    <arm_group_label>Hypertrophic cardiomyopathy</arm_group_label>
    <other_name>None - this is an observational study</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for genetic analysis and biomarkers will be obtained and retained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hypertrophic cardiomyopathy clinics Cardiology clinics Genetic clinics Hypertrophic
        Cardiomyopathy Association
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-65 with an established diagnosis of HCM defined as unexplained LVH
             defined as any segment â‰¥15mm thick, without a predisposing cause.

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior septal myectomy or alcohol septal ablation

          -  Prior myocardial infarction

          -  Incessant ventricular arrhythmias

          -  Inability to lie flat,

          -  Contraindication to CMR including pacemakers, defibrillators, intraocular metal,
             certain types of intracranial aneurysm clips, severe claustrophobia,

          -  Stage IV/V chronic kidney disease with glomerular filtration rate &lt;30 ml/min,

          -  Diabetes mellitus with end organ damage

          -  Pregnant female

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M Kramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Neubauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher M Kramer, MD</last_name>
    <phone>4342430736</phone>
    <email>ckramer@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Neubauer, MD</last_name>
    <phone>44 1865 221088</phone>
    <email>stefan.neubauer@cardiov.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Euan A Ashley, MRCP, DPhil</last_name>
      <phone>650-721-4363</phone>
      <email>euan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Euan A Ashley, MRCP, DPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Jacoby, MD</last_name>
      <phone>203-737-4551</phone>
      <email>daniel.jacoby@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Jacoby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lubna Choudhury, MD</last_name>
      <phone>312-695-4965</phone>
      <email>LChoudhury@nmff.org</email>
    </contact>
    <investigator>
      <last_name>Lubna Choudhury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodore P Abraham, MD</last_name>
      <phone>410-502-7974</phone>
      <email>tabraha3@jhmi.eduslangle1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore P Abraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolyn Ho, MD</last_name>
      <phone>617-732-7317</phone>
      <email>cho@partners.org</email>
    </contact>
    <investigator>
      <last_name>Carolyn Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin S Maron, MD</last_name>
      <phone>617-636-8066</phone>
      <email>mmaron@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Martin S Maron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-56444</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharlene M Day, MD</last_name>
      <phone>734-764-4500</phone>
      <email>sday@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Sharlene M Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Williamson, MD</last_name>
      <phone>507-284-2511</phone>
      <email>ewilliamson@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Williamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt University Hospital of Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark V Sherrid, MD</last_name>
      <phone>212-523-7370</phone>
      <email>Msherrid@chpnet.org</email>
    </contact>
    <investigator>
      <last_name>Mark V Sherrid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Han Kim, MD</last_name>
      <email>han.kim@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Han Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milind Y Desai, MD</last_name>
      <phone>216-445-5250</phone>
      <email>desaim2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Milind Y Desai, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Broberg, MD</last_name>
      <email>brobergc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Broberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew W Martinez, MD</last_name>
      <phone>610-402-9543</phone>
      <email>matthewwmartinez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Matthew W Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania (Penn Heart and Vascular Center)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anjali T Owens, MD</last_name>
      <phone>800-789-7366</phone>
      <email>anjali.owens@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Anjali T Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist DeBakey Cardiology Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sherif F Nagueh, MD</last_name>
      <phone>713-441-3963</phone>
      <email>SNagueh@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Sherif F Nagueh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher M Kramer, MD</last_name>
      <phone>434-243-0736</phone>
      <email>ckramer@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Salerno, MD, PhD</last_name>
      <phone>4349826135</phone>
      <email>ms5pc@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Salerno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James White, MD</last_name>
      <phone>403-944-8806</phone>
      <email>jwhite.imaging@gmail.com</email>
    </contact>
    <investigator>
      <last_name>James White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Research Institute (TGRI), Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry Rakowski, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>4062</phone_ext>
      <email>harry.rakowski@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Harry Rakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute (Institut de Cardiologie de Montreal)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias G Friedrich, MD</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>2753</phone_ext>
      <email>Matthias.friedrich@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Matthias G Friedrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanette Schulz-Menger, MD</last_name>
      <phone>+49 30 9401 52903</phone>
      <phone_ext>53536</phone_ext>
      <email>jeanette.schulz-menger@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jeanette Schulz-Menger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitats Klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugo A Katus, MD</last_name>
      <phone>+49 6221 56 4130</phone>
      <email>sekretariat.katus@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Hugo A Katus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus GmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Udo Sechtem, MD</last_name>
      <phone>+49 711 810 16048</phone>
      <email>udo.sechtem@rbk.de</email>
    </contact>
    <investigator>
      <last_name>Udo Sechtem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Bigini, MD</last_name>
      <phone>+39 051 349 858</phone>
      <email>elena.biagini73@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Bigini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iacopo Olivotto, MD</last_name>
      <phone>+39 055 7945138</phone>
      <email>iacopo.olivotto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iacopo Olivotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele University Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Camici, MD</last_name>
      <phone>+39 0226436206</phone>
      <email>camici.paolo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Paolo G Camici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sapienza University</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camillo Autore, MD</last_name>
      <phone>+39 0633775868</phone>
      <email>camillo.autore@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Camillo Autore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert C van Rossum, MD</last_name>
      <phone>+31 20442244</phone>
      <email>ac.vrossum@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Albert C van Rossum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Michels, MD, PhD</last_name>
      <phone>+31 10 7035548</phone>
      <email>m.michels@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Michelle Michels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Aberdeen, School of Medicine and Dentistry</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Frenneaux, PhD</last_name>
      <phone>+44 (0) 1224 437970</phone>
      <email>m.p.frenneaux@abdn.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Frenneaux, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Glasgow (BHF Glasgow Cardiovascular Research Centre)</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolaos Tzemos, MD</last_name>
      <phone>+44 (0) 141 330 2079</phone>
      <email>niko.tzemos@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Tzemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham (Queen Elizabeth Hospital)</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Leyva, MD</last_name>
      <phone>+44 0121 371 4621</phone>
      <email>francisco.leyva@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Francisco Leyva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Newby, MD</last_name>
      <phone>+44 131 242 6422</phone>
      <email>D.E.Newby@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>David Newby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven Plein, MD</last_name>
      <phone>+44 113 3437720</phone>
      <email>s.plein@leeds.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sven Plein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerry P McCann, MD</last_name>
      <phone>+44 (0)1162 583977</phone>
      <email>Gerry.mccann@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gerry P McCann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College London (St. Thomas' Hospital)</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eike Nagel, MD</last_name>
      <phone>+44 20 7188 7242</phone>
      <email>eike.nagel@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Eike Nagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Prasad, MD</last_name>
      <phone>+44 20 7352 8121</phone>
      <phone_ext>2919</phone_ext>
      <email>s.prasad@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sanjay Prasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sam A Mohiddin, MD</last_name>
      <phone>+44 (0)0208 983 2457</phone>
      <email>smohiddin@doctors.org.uk</email>
    </contact>
    <investigator>
      <last_name>Sam A Mohiddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George's Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Sharma, MD</last_name>
      <phone>+44 (0) 208 725 1390</phone>
      <email>sasharma@sgul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sanjay Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertrophic cardiomyopathy</keyword>
  <keyword>Cardiac magnetic resonance imaging</keyword>
  <keyword>CMR</keyword>
  <keyword>Genetics</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Late gadolinium enhancement</keyword>
  <keyword>T1 mapping</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
